[go: up one dir, main page]

WO2000069901A3 - Proteins with insulin-like activity useful in the treatment of diabetes - Google Patents

Proteins with insulin-like activity useful in the treatment of diabetes Download PDF

Info

Publication number
WO2000069901A3
WO2000069901A3 PCT/US2000/013764 US0013764W WO0069901A3 WO 2000069901 A3 WO2000069901 A3 WO 2000069901A3 US 0013764 W US0013764 W US 0013764W WO 0069901 A3 WO0069901 A3 WO 0069901A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
proteins
insulin
treatment
activity useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013764
Other languages
French (fr)
Other versions
WO2000069901A2 (en
Inventor
Bassil I Dahiyat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to AU51444/00A priority Critical patent/AU5144400A/en
Priority to JP2000618317A priority patent/JP2003518917A/en
Priority to CA002372393A priority patent/CA2372393A1/en
Publication of WO2000069901A2 publication Critical patent/WO2000069901A2/en
Anticipated expiration legal-status Critical
Publication of WO2000069901A3 publication Critical patent/WO2000069901A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention relates to novel insulin activity (IA) proteins and nucleic acids. The invention further relates to the use of the IA proteins in the treatment of insulin related disorders such as type 1 diabetes and type 2 diabetes.
PCT/US2000/013764 1999-05-19 2000-05-19 Proteins with insulin-like activity useful in the treatment of diabetes Ceased WO2000069901A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU51444/00A AU5144400A (en) 1999-05-19 2000-05-19 Novel proteins with insulin-like activity useful in the treatment of diabetes
JP2000618317A JP2003518917A (en) 1999-05-19 2000-05-19 Novel protein with insulin-like activity useful for the treatment of diabetes
CA002372393A CA2372393A1 (en) 1999-05-19 2000-05-19 Novel proteins with insulin-like activity useful in the treatment of diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13493099P 1999-05-19 1999-05-19
US60/134,930 1999-05-19

Publications (2)

Publication Number Publication Date
WO2000069901A2 WO2000069901A2 (en) 2000-11-23
WO2000069901A3 true WO2000069901A3 (en) 2002-09-12

Family

ID=22465651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013764 Ceased WO2000069901A2 (en) 1999-05-19 2000-05-19 Proteins with insulin-like activity useful in the treatment of diabetes

Country Status (4)

Country Link
JP (1) JP2003518917A (en)
AU (1) AU5144400A (en)
CA (1) CA2372393A1 (en)
WO (1) WO2000069901A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
PT1141015E (en) 1999-01-06 2009-10-13 Genentech Inc Insulin-like growth factor (igf) i mutant variants
ES2301547T3 (en) 2000-05-16 2008-07-01 Genentech, Inc. TREATMENT OF CARTILAGO DISORDERS.
WO2005005477A2 (en) * 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
AU2007298919C1 (en) * 2006-09-22 2014-02-06 Novo Nordisk A/S Protease resistant insulin analogues
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
KR101755434B1 (en) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 Protease stabilized, acylated insulin analogues
JP2012511506A (en) * 2008-12-09 2012-05-24 ノヴォ・ノルディスク・アー／エス New insulin analogue
JP2014509603A (en) 2011-03-15 2014-04-21 ノヴォ ノルディスク アー／エス Human insulin analogues and human insulin derivatives containing cysteine substitutions
RS57004B1 (en) 2013-10-07 2018-05-31 Novo Nordisk As Novel derivative of an insulin analogue
DK3554534T3 (en) 2016-12-16 2021-08-23 Novo Nordisk As PHARMACEUTICAL COMPOSITION INCLUDING INSULIN
RU2020108281A (en) * 2017-08-17 2021-08-26 Ново Нордиск А/С NEW ACYLATED ANALOGUES OF INSULIN AND VERSIONS OF THEIR APPLICATION
CN112843082B (en) * 2021-02-02 2022-07-05 四川大学 Application of DNA tetrahedron in preparation of medicine for treating diabetes
CN112843081B (en) * 2021-02-02 2022-07-05 四川大学 DNA tetrahedron-resveratrol compound and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003174A1 (en) * 1991-08-08 1993-02-18 Scios Inc. Tissue-selective insulin analogs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003174A1 (en) * 1991-08-08 1993-02-18 Scios Inc. Tissue-selective insulin analogs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. MOL. BIOL. INT. (1997), 43(4), 705-711 *
BIOCHIM. BIOPHYS. ACTA (1998), 1429(1), 69-73 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BRANGE, J. ET AL: "Design of novel insulins with changed self-association and ligand binding properties", XP002167132, retrieved from STN Database accession no. 115:85565 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, HUI ET AL: "Hydrophilic Thr can replace the hydrophobic and absolutely conservative A3Val in insulin", XP002167130, retrieved from STN Database accession no. 130:192138 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SASAKI, ATSUKO ET AL: "Tertiary structure analysis of receptor binding ability of mutant insulins", XP002167133, retrieved from STN Database accession no. 115:985 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHI, MIN ET AL: "Studies on growth-promoting action of insulin: mitogenic activity of insulin and its analogs in mouse mammary tumor cells", XP002167131, retrieved from STN Database accession no. 128:149680 *
GBF MONOGR. (1989), 12(ADV. PROTEIN DES.), 139-44 *
JIKEIKAI MED. J. (1990), 37(3), 343-53 *
NAKAGAWA, SATOE H. ET AL: "Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions", BIOCHEMISTRY (1992), 31(12), 3204-14, XP002167129 *

Also Published As

Publication number Publication date
CA2372393A1 (en) 2000-11-23
AU5144400A (en) 2000-12-05
JP2003518917A (en) 2003-06-17
WO2000069901A2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
WO2000068387A3 (en) Nucleic acids and proteins with interferon-beta activity
WO2000069901A3 (en) Proteins with insulin-like activity useful in the treatment of diabetes
WO2000074666A3 (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
AU3791799A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO2003059934A3 (en) Albumin fusion proteins
EP0926159A3 (en) Glucagon-like peptide-1 crystals
CA2257133A1 (en) Human dnase i hyperactive variants
AU5210798A (en) Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use
AU2003234529A1 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
AU6701890A (en) Process for the production of biologically active protein
EP2298355A3 (en) Albumin fusion proteins
PL346520A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
CA2295999A1 (en) Nik proteins, nucleic acids and methods
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
WO2000053776A3 (en) Human kallikrein-like genes
WO2003092612A3 (en) VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
AU2670495A (en) Ifn-beta liquid formulations
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
EP0749312A4 (en) -i(DIROFILARIA IMMITIS) Gp29 PROTEINS, NUCLEIC ACID MOLECULES AND USES THEREOF
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
WO1999033989A3 (en) Rantes mutants and therapeutic applications thereof
DE69837148D1 (en) CHIMERIC PROTEINS FOR THE TREATMENT OF DIABETES
WO2002004521A3 (en) Proteins with integrin-like activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2372393

Country of ref document: CA

Ref country code: CA

Ref document number: 2372393

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 618317

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 51444/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000936077

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000936077

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG